Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Naveed Shaik

Glasdegib in Combination With Cytarabine and Daunorubicin in Patients With AML or High-Risk MDS: Phase 2 Study Results

American Journal of Hematology

Hematology

2018

English

Evaluation of the Effect of Rifampin on the Pharmacokinetics of the Smoothened Inhibitor Glasdegib in Healthy Volunteers

British Journal of Clinical Pharmacology

Pharmacology

2018

English

Related publications

Phase I Dose Escalation Study of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

English

Final Results of a Phase 2, Open-Label Study of Indisulam, Idarubicin, and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

English

Transplant Conditioning With Treosulfan/Fludarabine With or Without TBI. A Randomized Phase II Trial in Patients With MDS and AML

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2018

English

A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia

Journal of Hematology and Oncology

English

5O_PRA Phase 1b/2 Study of Omaveloxolone in Combination With Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

English

Results of a Prospective Phase 2 Study of Pazopanib in Patients With Advanced Intermediate-Grade or High-Grade Liposarcoma

English

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS

English

A Phase I Study of Intravenous Liposomal Daunorubicin (DaunoXome) in Paediatric Patients With Relapsed or Resistant Solid Tumours

British Journal of Cancer

Cancer Research

Oncology

2006

English

Intesive Fludarabine-High Dose Cytarabine-Idarubicin Combination as Induction Therapy With Risk-Adapted Consolidation May Improve Treatment Efficacy in Younger Acute Myeloid Leukemia (AML) Patients: Rationales, Evidences and Future Perspectives

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Naveed Shaik

Glasdegib in Combination With Cytarabine and Daunorubicin in Patients With AML or High-Risk MDS: Phase 2 Study Results

Evaluation of the Effect of Rifampin on the Pharmacokinetics of the Smoothened Inhibitor Glasdegib in Healthy Volunteers

Related publications

Phase I Dose Escalation Study of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Final Results of a Phase 2, Open-Label Study of Indisulam, Idarubicin, and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Transplant Conditioning With Treosulfan/Fludarabine With or Without TBI. A Randomized Phase II Trial in Patients With MDS and AML

A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia

5O_PRA Phase 1b/2 Study of Omaveloxolone in Combination With Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

Results of a Prospective Phase 2 Study of Pazopanib in Patients With Advanced Intermediate-Grade or High-Grade Liposarcoma

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS

A Phase I Study of Intravenous Liposomal Daunorubicin (DaunoXome) in Paediatric Patients With Relapsed or Resistant Solid Tumours

Intesive Fludarabine-High Dose Cytarabine-Idarubicin Combination as Induction Therapy With Risk-Adapted Consolidation May Improve Treatment Efficacy in Younger Acute Myeloid Leukemia (AML) Patients: Rationales, Evidences and Future Perspectives